A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study
-
Published:2023-12
Issue:
Volume:195
Page:113373
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Yamada TadaakiORCID,
Goto Yasuhiro,
Tanaka Hiroshi,
Kimura Hideharu,
Minato Koichi,
Gyotoku HiroshiORCID,
Honda TakeshiORCID,
Watanabe SatoshiORCID,
Morimoto KenjiORCID,
Kiyomi Fumiaki,
Uchino JunjiORCID,
Takayama KoichiORCID
Funder
AstraZeneca KK
AstraZeneca
Subject
Cancer Research,Oncology
Reference20 articles.
1. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer;Furuse;J Clin Oncol,1999
2. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. a meta-analysis;Pritchard;Ann Intern Med,1996
3. Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017
4. Stage III non-small cell lung cancer in the elderly: patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice;Driessen;Radiother Oncol,2016
5. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study;De Ruysscher;Ann Oncol,2009
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献